Retinal Vein Occlusion (RVO) Treatment Market Trends

Retinal Vein Occlusion Treatment Market Trends

Increased funding and research activities are leading to the development of advanced therapeutic options such as novel anti-VEGF therapies and sustained-release corticosteroid implants along with other therapy interventions. These advancements tend to improve treatment efficacy and patient outcomes further fostering the market demand. Also, ongoing clinical trials and new product launches enhance market growth by expanding available treatment options and improving disease management strategies.
 

• For instance, Roche introduced new 72-week data from two global Phase III studies, BALATON (NCT04740905) and COMINO (NCT04740931), evaluating faricimab (Vabysmo) for macular edema due to BRVO and CRVO. The findings indicated that nearly 60% of participants in the BALATON trial and up to 48% in the COMINO trial were able to extend their treatment intervals to three or four months after Vabysmo administration. This significant improvement compared to the typical one to two-month intervals for existing RVO treatments resulted in reinforcing efficacious treatment options for retinal conditions causing vision loss. Such trials in pipeline is expected to spur the market growth.
   

Moreover, the growing aging population with vision complications, strategic expansions by key players, increasing approvals, and advancements in drug delivery are further boosting market demand.